Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 8025271, 5 pages
http://dx.doi.org/10.1155/2016/8025271
Research Article

Diagnostic Utility of Neuregulin for Acute Coronary Syndrome

1Department of Emergency Medicine, Vanderbilt University School of Medicine, 703 Oxford House, 1313 21st Avenue S., Nashville, TN 37232, USA
2Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Received 4 December 2015; Accepted 17 February 2016

Academic Editor: Mariann Harangi

Copyright © 2016 Maame Yaa A. B. Yiadom et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The purpose of this study was to determine the diagnostic test characteristics of serum neuregulin-1β (NRG-1β) for the detection of acute coronary syndrome (ACS). We recruited emergency department patients presenting with signs and symptoms prompting an evaluation for ACS. Serum troponin and neuregulin-1β levels were compared between those who had a final discharge diagnosis of myocardial infarction (STEMI and NSTEMI) and those who did not, as well as those who more broadly had a final discharge diagnosis of ACS (STEMI, NSTEMI, and unstable angina). Of 319 study participants, 11% had evidence of myocardial infarction, and 19.7% had a final diagnosis of ACS. Patients with MI had median neuregulin levels of 0.16 ng/mL (IQR [0.16–24.54]). Compared to the median of those without MI, 1.46 ng/mL (IQR [0.16–15.02]), there was no significant difference in the distribution of results (). Median neuregulin levels for patients with ACS were 0.65 ng/mL (IQR [0.16–24.54]). There was no statistical significance compared to those without ACS who had a median of 1.40 ng/mL (IQR [0.16–14.19]) (). Neuregulin did not perform successfully as a biomarker for acute MI or ACS in the emergency department.